Related references
Note: Only part of the references are listed.Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence
Matthew E. Falagas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Oren Zusman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia
Julio Ramirez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
Emanuele Durante-Mangoni et al.
CLINICAL INFECTIOUS DISEASES (2013)
The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp treated with ampicillin/sulbactam
Maura S. de Oliveira et al.
CLINICS (2013)
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
R. P. Dellinger et al.
INTENSIVE CARE MEDICINE (2013)
β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: A meta-analysis
Konstantinos Z. Vardakas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality
Alicia Hernandez-Torres et al.
MEDICINA CLINICA (2012)
Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Infections among Solid Organ Transplant Recipients
Ryan K. Shields et al.
PLOS ONE (2012)
Is Tigecycline a Good Choice in the Treatment of Multidrug-Resistant Acinetobacter baumannii Pneumonia?
M. S. Tasbakan et al.
JOURNAL OF CHEMOTHERAPY (2011)
The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii
Jung-Jr Ye et al.
JOURNAL OF INFECTION (2011)
The Outcomes of Using Colistin for Treating Multidrug Resistant Acinetobacter Species Bloodstream Infections
Seung-Kwan Lim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2011)
In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore
Tze-Peng Lim et al.
PLOS ONE (2011)
Treatment of Acinetobacter infections
Argyris Michalopoulos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii
Murat Dizbay et al.
JOURNAL OF ANTIBIOTICS (2010)
Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections
Ronald Gounden et al.
BMC INFECTIOUS DISEASES (2009)
Nephrotoxicity of Colistin: New Insight into an Old Antibiotic
Matthew E. Falagas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
M. S. Oliveira et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia
Alex P. Betrosian et al.
JOURNAL OF INFECTION (2008)
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections
Drosos E. Karageorgopoulos et al.
LANCET INFECTIOUS DISEASES (2008)
Acinetobacter infections:: a growing threat for critically ill patients
M. E. Falagas et al.
EPIDEMIOLOGY AND INFECTION (2008)
Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases
Marie-Francoise Tripodi et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii
Yu-Chen Tseng et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2007)
Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials
Liat Vidal et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Multidrug-resistant Acinetobacter baumannii bacteraemia:: clinical features, antimicrobial therapy and outcome
L. -C. Kuo et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii
Alex P. Betrosian et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2007)
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Anton Y. Peleg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)
AC Gales et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
The role of aminoglycosides in combination with a β-lactam for the treatment of bacterial endocarditis:: a meta-analysis of comparative trials
ME Falagas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies
Matthew E. Falagas et al.
CRITICAL CARE (2006)
Overview of nosocomial infections caused by gram-negative bacilli
R Gaynes et al.
CLINICAL INFECTIOUS DISEASES (2005)
Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance:: A meta-analysis of randomized, controlled trials
IA Bliziotis et al.
CLINICAL INFECTIOUS DISEASES (2005)
Treatment of pan-drug resistant Acinetobacter baumannii
CM Lee et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2005)
Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
[Anonymous]
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii
J Yoon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain
WC Ko et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Antimicrobial resistance of Acinetobacter spp. in Europe
M Van Looveren et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model
A Montero et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia
GC Wood et al.
CLINICAL INFECTIOUS DISEASES (2002)
Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem
AS Levin
CLINICAL MICROBIOLOGY AND INFECTION (2002)
Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains
MJ Rodríguez-Hernández et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2001)
Accuracy and reliability of APACHE II scoring in two intensive care units - Problems and pitfalls in the use of APACHE II and suggestions for improvement
KH Polderman et al.
ANAESTHESIA (2001)
Validation of severity scoring systems SAPS II and APACHE II in a single-center population
M Capuzzo et al.
INTENSIVE CARE MEDICINE (2000)